OncoMatch/Clinical Trials/NCT06288360
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
Is NCT06288360 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Camrelizumab and Paclitaxel-albumin for cervical cancer.
Treatment: Camrelizumab · Paclitaxel-albumin · Cisplatin — This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Cervical Cancer
Biomarker criteria
Required: PD-L1 (CD274) negative expression (combined positive score < 1)
Disease stage
Required: Stage IIB, IIIC1R
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: immune checkpoint inhibitor
Prior treatment with immune checkpoint inhibitors, including, but not limited to, other anti-PD-1, anti-PD-L1 antibodies, CTLA-4 antibodies, or antibodies against immune co-stimulators (e.g., antibodies against ICOS, CD40, CD137, GITR, OX40 targets, etc.), or any other therapy targeting a tumor's immune mechanism of action
Lab requirements
Blood counts
wbc≥3.5*10^9/l, neu≥1.5*10^9/l, platelet≥100×10^9 /l
Kidney function
serum creatinine and blood urea nitrogen ≤the upper limit of normal value
Liver function
ast and alt ≤1.5 times normal upper limit; total bilirubin ≤1.5 times the upper limit of normal value
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06288360 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 negative expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIB or IIIC1R is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages